Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122301 · ClinicalTrials.gov registry record · Phase 2
Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03122301 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 2 participants.
The verdict
NCT03122301, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Vasomotor symptoms (hot flashes, night sweats, VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. VMS in Hispanic women are significantly more severe as compared to non-Hispanic Caucasian women. Few effective treatments for VMS are available, especially in the underserved Hispanic and Spanish-speaking populations which is problematic, as Hispanics will comprise 20% of the U.S. population by 2025. Stellate ganglion nerve block (SGB) with local anesthetic, previously performed for chronic pain indications, has shown promise as a potential treatment for menopausal women with VMS in previous clinical trials, but has not been investigated in Hispanic or Spanish-Speaking women with breast cancer in a controlled study.
Interventions
- DRUG Saline
- DRUG Stellate Ganglion Block injection with bupivicaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122301
The ClinicalTrials.gov registry entry for NCT03122301 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT03122301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122301 about?
NCT03122301 is a clinical study titled "Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer". Vasomotor symptoms (hot flashes, night sweats, VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. VMS in Hispanic women are significantly more severe as compared to non-Hispanic Caucasian women. Few effective treatments for VMS are available, especially in ...
What is the current status of trial NCT03122301?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-06-01. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT03122301?
The interventions under investigation include: Saline (DRUG), Stellate Ganglion Block injection with bupivicaine (DRUG).
Who is sponsoring clinical trial NCT03122301?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.